Rapid health technology assessment of six non-ergot dopamine-receptor agonists for the treatment of early Parkinson's disease.

ABSTRACT:

Purpose

Six non-ergot dopamine -receptor agonists (NEDAs), including pramipexole extended-release (ER), pramipexole immediate-release (IR), rotigotine patch, piribedil, ropinirole prolonged-release (PR), and ropinirole IR, are frequently used to treat early Parkinson's disease (PD). However, there is a paucity of comparative information about them. For making rational drug selections, six NEDAs were evaluated using a rapid health technology assessment method.

Methods

According to the rapid guidelines for drug evaluation and selection in Chinese medical institutions (the Second Edition), the pharmacological properties, efficacy, safety, economy, and other attributes of six NEDAs were scored on a percentage system.

Results

The composite scores of the six NEDAs are prese

SUBMITTER: Lv J 

PROVIDER: S-EPMC12753440 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature